Eyeworld CME Supplements

EW JUL 2013 - Supported by Bausch + Lomb

This is a supplement to EyeWorld Magazine that doctors can take a test after reading and receive CME credits for.

Issue link: http://cmesupplements.eyeworld.org/i/146117

Contents of this Issue

Navigation

Page 0 of 7

ASCRS This CME supplement is supported by an unrestricted educational grant from Bausch + Lomb. Supplement to EyeWorld July 2013 Inflammation and success in refractive cataract surgery New anti-inflammatory therapeutics "There are factors that we know have helped improve outcomes in patients who are receiving advanced technology IOLs," said Terry Kim, MD, professor of ophthalmology, Duke University School of Medicine, Durham, N.C. Among the more familiar factors are patient selection, improved biometry and keratometry, OCT imaging, and femtosecond laser technology. One variable tends to be overlooked in terms of how important it is to the outcomes of refractive cataract procedures: inflammation. The goal with these procedures, said Dr. Kim, should be to eliminate post-cataract inflammation. Dr. Kim joined a faculty of experts to look at "Knocking Down Inflammatory Barriers to Success in Refractive Cataract Surgery" at an EyeWorld CME Education symposium held at the 2013 ASCRS•ASOA Symposium & Congress. Their objectives were to recognize the impact of ocular inflammation on outcomes in refractive cataract surgery, understand the role of antiinflammatory therapies in mediating and preventing anterior and posterior segment ocular tissue response throughout the inflammatory cascade, and identify strategies to prevent edema and relieve pain by maximizing the formulation of anti-inflammatory agents to enhance their penetration into target tissues. "A lot of us are not aware of some of the recent advances in therapeutic agents," said Dr. Kim. "We've had some new and exciting developments in terms of our choices for anti-inflammatory therapy with regard to both topical corticosteroids and nonsteroidal agents," he said. In terms of nonsteroidal anti-inflammatory drugs (NSAIDs), there have been some notable reformulations of familiar agents. Prolensa (bromfenac 0.07%), which received FDA approval in April, provides a lower concentration of the active ingredient than Bromday (bromfenac 0.09%). The new drug is approved for once-a-day daily dosing 1 day preop, the day of surgery, and 14 days postoperatively. Financial Interest Disclosures The faculty have disclosed the following financial interest relationships within the last 12 months: Francis S. Mah, MD, has received a retainer, ad hoc fees, or other consulting income from: Alcon, ForSight Labs, and ISTA. He is a member of the speakers bureau of Allergan and Bausch & Lomb. David F. Chang, MD, has received a retainer, ad hoc fees, or other consulting income from: Abbott Medical Optics, Clarity Medical Systems, LensAR, and Transcend. He is a member of the speakers bureaus of:Allergan and Zeiss Certified. He has received research funding from Glaukos. Dr. Chang has investment interests in Calhourn Vision, ICON Bioscience, PowerVision, and Revital Vision. He receives a royalty or other financial gain from Eyemaginations and SLACK Inc. Keith A. Warren, MD, has received a retainer, ad hoc fees, or other consulting income and is a member of the speakers bureau of: Alcon, Dutch Ophthalmic USA, and Genentech. Uday Devgan, MD, has received a retainer, ad hoc fees, or other consulting income from: Aaren Scientific, Bausch & Lomb, Gerson Lehman Group, Hoya Vision Care, and ISTA. He is a member of the speakers bureau for Alcon. Dr. Devgan has an investment interest in Specialty Surgical and receives a royalty or other financial gain from Accutome. Staff member Laura Johnson has no financial interests to disclose. Terry Kim, MD, has received a retainer, ad hoc fees, or other consulting income from: Alcon, Bausch & Lomb, ISTA, Ocular Systems, Ocular Therapeutix, PowerVision, and SARCode Bioscience. Accreditation Statement This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the American Society of Cataract and Refractive Surgery (ASCRS) and EyeWorld. ASCRS is accredited by the ACCME to provide continuing medical education for physicians. Educational Objectives Ophthalmologists who participate in this course will: • Identify the impact of ocular inflammation on outcomes in refractive cataract surgery; • Understand the role of anti-inflammatory therapies in mediating or preventing ocular tissue response throughout the inflammatory cascade; and • Identify strategies to prevent edema and relieve pain by maximizing the penetration vehicle of anti-inflammatory agents into target tissues. Designation Statement The American Society of Cataract and Refractive Surgery designates this live educational activity for a maximum of 0.5 AMA PRA Category 1 Credits.™ Physicians should claim only credit commensurate with the extent of their participation in the activity. Claiming Credit To claim credit, participants must visit www.CMESupplement.eyeworld.org to review educational content and download the post-activity test and credit claim. All participants must pass the post-activity test with a score of 75% or higher to earn credit. Standard internet access is required. Adobe Acrobat Reader is needed to view the materials. CME credit is valid through January 30, 2014. CME credit will not be awarded after that date. Notice of Off-Label Use Presentations This activity may include presentations on drugs or devices or uses of drugs or devices that may not have been approved by the Food and Drug Administration (FDA) or have been approved by the FDA for specific uses only. ADA/Special Accommodations ASCRS and EyeWorld fully comply with the legal requirements of the Americans with Disabilities Act (ADA) and the rules and regulations thereof. Any participant in this educational program who requires special accommodations or services should contact Laura Johnson at ljohnson@ascrs.org or 703-591-2220.

Articles in this issue

Links on this page

Archives of this issue

view archives of Eyeworld CME Supplements - EW JUL 2013 - Supported by Bausch + Lomb